Search
17-hydroxyprogesterone (Duralutin, Makena, Prodrox)
Pharmacology:
Tradename: Duralutin, Makena (caproate)
Indications:
1) treatment of amenorrhea
2) abnormal uterine bleeding
3) submucous fibroids
4) endometriosis
5) uterine carcinoma
6) testing of estrogen production
7) to reduce the risk for preterm labor & preterm delivery
Dosage:
1) amenorrhea:
a) 375 mg IM
b) if no bleeding, begin cyclic treatment with estradiol valerate
2) test for endogenous estrogen production:
a) 250 mg at any time during the estrous cycle
b) bleeding 7-14 days after injection indicates positive test
3) risk for preterm delivery (Makena)
- injection into the hip once a week, beginning at 16 weeks of pregnancy, up to 21 weeks [2]
Injection: 250 mg/mL (5 mL).
Adverse effects:
1) common (> 10%)
- edema, breakthrough bleeding, spotting, changes in menstrual flow, amenorrhea, anorexia, pain at site of injection, weakness
2) less common (1-10%)
- edema, mental depression, insomnia, fever, melasma, chloasma, rash, pruritus, weight gain or loss, changes in cervical erosions & secretions, increased breast tenderness, cholestatic jaundice
Interactions
molecular events
Related
17-hydroxyprogesterone in serum/plasma
steroid biosynthesis
General
17 hydroxycorticosteroid
adrenal cortex hormone; corticosteroid
endocrine agent
progesterone (Progestasert, Prometrium, Pro-Gest, Prochieve)
Properties
MISC-INFO: pregnancy-category D
Database Correlations
PUBCHEM cid=6238
References
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- FDA Press Release, Feb 4, 2011
FDA approves drug to reduce risk of preterm birth in at-risk pregnant women
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm242234.htm